Business
7 views
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
CNBC Verified Source
Syndicated via official news feed
Explore all Business stories
Syndicated feed content with full publisher credit.
Business Desk
More in Business
Continue reading verified coverage and related developments on this desk.